Prognostic value of sST2 added to XXXX in @entity712 with preserved or reduced ejection fraction.

@entity1 @entity712 @entity308 @entity3876 @entity8389 @entity204
BACKGROUND: Natriuretic peptides and @entity8389 ( @entity8389 ) represent two different physiopathological pathways. We evaluated the prognostic accuracy and complementarity of @entity3876 ( @entity3876 ) and soluble @entity8389 (sST2) plasma levels at discharge from a hospital admission for @entity712 , both in @entity1 with preserved (HFpEF) and @entity308 (HFrEF) systolic function. METHODS AND RESULTS: We enrolled 195 consecutive @entity1 discharged alive and followed them prospectively for 6  months. The endpoint was all-cause @entity204 or hospital readmission for @entity712 . Seventy-six @entity1 had HFpEF and 119 had HFrEF, of whom 23 (30.3  %) and 43 (36.1  %) reached the combined endpoint, respectively. In both HFpEF and HFrEF, having the two biomarkers into account added prognostic information, with the highest risk in @entity1 with both biomarkers above the median in their group (approximately 40  % hospitalization-free survival in both groups at 6  months). These associations translated into a significant fourfold increase in risk of the endpoint for one elevated biomarker and sevenfold for both biomarkers elevated in HFrEF, and no association for one elevated biomarker and fivefold increase in risk for both biomarkers elevated in HFpEF. Considering the reclassification of risk added to @entity3876 by measurement of sST2, net reclassification index was 0.31 (p  =  0.21) among @entity1 with HFpEF and 0.70 (p  <  0.001) among @entity1 with HFrEF. CONCLUSIONS: sST2 provides robust prognostic information in @entity712 with HFrEF, while this pattern was less clear in HFpEF. When sST2 was measured together with @entity3876 , it improved prognostic accuracy in both groups, more clearly in HFrEF.
